Journal Article

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

Mencoboni, Manlio, Piccirillo, Maria Carmela, Gridelli, Cesare, Quantin, Xavier, Zalcman, Gerard, Pagano, Maria, Scherpereel, Arnaud, Grosso, Federica, Gargiulo, Piera, Lantuejoul, Sylvie, Cecere, Fabiana Letizia, Delfanti, Sara, Morabito, Alessandro, Dawe, David E, Sederias, Joana, Tsao, Ming-Sound, Sanchez, Myriam Locatelli, Westeel, Virginie, Perrone, Francesco, Laurie, Scott A, Ceresoli, Giovanni Luca, Tu, Dongsheng, Lo Russo, Giuseppe, Zucali, Paolo Andrea, Brown-Walker, Pamela, Tu, Wei, Greillier, Laurent, Luo, Yiwen, Chu, Quincy, Lee, Christopher W, Florescu, Marie, Goffin, John R, Bradbury, Penelope, Leighl, Natasha, Seymour, Lesley

2023

Overview

Pleural mesothelioma usually presents at an advanced, incurable stage. Chemotherapy with platinum–pemetrexed is a standard treatment. We hypothesised that the addition of pembrolizumab to platinum–pemetrexed would improve overall survival in patients with pleural mesothelioma. We did this open-label, international, randomised phase 3 trial at 51 hospitals in Canada, Italy, and France. Eligible participants were aged 18 years or older, with previously untreated advanced pleural mesothelioma, with an Eastern Cooperative Oncology Group performance status score of 0 or 1. Patients were randomly assigned (1:1) to intravenous chemotherapy (cisplatin [75 mg/m2] or carboplatin [area under the concentration-time curve 5–6 mg/mL per min] with pemetrexed 500 mg/m2, every 3 weeks for up to 6 cycles), with or without intravenous pembrolizumab 200 mg every 3 weeks (up to 2 years). The primary endpoint was overall survival in all randomly assigned patients; safety was assessed in all randomly assigned patients who received at least one dose of study therapy. This trial is registered with ClinicalTrials.gov, NCT02784171, and is closed to accrual. Between Jan 31, 2017, and Sept 4, 2020, 440 patients were enrolled and randomly assigned to chemotherapy alone (n=218) or chemotherapy with pembrolizumab (n=222). 333 (76 %) of patients were male, 347 (79%) were White, and median age was 71 years (IQR 66–75). At final analysis (database lock Dec 15, 2022), with a median follow-up of 16·2 months (IQR 8·3–27·8), overall survival was significantly longer with pembrolizumab (median overall survival 17·3 months [95% CI 14·4–21·3] with pembrolizumab vs 16·1 months [13·1–18·2] with chemotherapy alone, hazard ratio for death 0·79; 95% CI 0·64–0·98, two-sided p=0·0324). 3-year overall survival rate was 25% (95% CI 20–33%) with pembrolizumab and 17% (13–24%) with chemotherapy alone. Adverse events related to study treatment of grade 3 or 4 occurred in 60 (27%) of 222 patients in the pembrolizumab group and 32 (15%) of 211 patients in the chemotherapy alone group. Hospital admissions for serious adverse events related to one or more study drugs were reported in 40 (18%) of 222 patients in the pembrolizumab group and 12 (6%) of 211 patients in the chemotherapy alone group. Grade 5 adverse events related to one or more drugs occurred in two patients on the pembrolizumab group and one patient in the chemotherapy alone group. In patients with advanced pleural mesothelioma, the addition of pembrolizumab to standard platinum–pemetrexed chemotherapy was tolerable and resulted in a significant improvement in overall survival. This regimen is a new treatment option for previously untreated advanced pleural mesothelioma. The Canadian Cancer Society and Merck & Co.

• Publisher: Elsevier Ltd,Elsevier Limited,Elsevier
• Subject: Adverse events / Aged / Antineoplastic Combined Chemotherapy Protocols / Canada - epidemiology / Cancer / Cancer therapies / Carboplatin / Cell death / Chemotherapy / Cisplatin / Drugs / Female / Health economics / Histology / Hospitals / Humans / Immunotherapy / Intravenous administration / Labels / Laboratories / Life Sciences / Lung cancer / Male / Mesothelioma / Mesothelioma - chemically induced / Mesothelioma - drug therapy / Mesothelioma, Malignant - drug therapy / Monoclonal antibodies / Patients / Pembrolizumab / Pemetrexed - adverse effects / Platinum / Platinum - therapeutic use / Quality of life / Response rates / Statistical analysis / Survival / Targeted cancer therapy